A simulation-based confidence band for drug concentrations in blood: an application to a clinical phase I trial

The Graduate University for Advanced Studies, Миура, Kanagawa, Japan
Statistics in Medicine (Impact Factor: 1.83). 10/2003; 22(19):3045-53. DOI: 10.1002/sim.1543
Source: PubMed


Since drug concentrations in blood are usually related to the effectiveness and toxicity, a confidence band for the drug concentrations gives useful information for the treatment. This paper proposes a simulation-based approach for constructing confidence bands for drug concentrations in blood. The confidence band covers the whole profile of the drug concentrations with a specified probability. The proposed approach presupposes that actual concentrations of a subject fluctuate randomly around a curve specified by an appropriate pharmacokinetic model and the subject-specific pharmacokinetic parameters. The confidence band is constructed by taking into account both the random fluctuations of the actual concentrations and the statistical uncertainty of the parameter estimates. The proposed approach is applied to a simulation study and an actual phase I trial.

0 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: A fundamental assumption underlying pharmacokinetic compartment modelling is that each subject has a different individual curve. To some extent this runs counter to the statistical principle that similar individuals will have similar curves, thus making inferences to a wider population possible. In population pharmacokinetics, the compromise is to use random effects. We recommend that such models also be used in data rich situations instead of independently fitting individual curves. However, the additional information available in such studies shows that random effects are often not sufficient; generally, an autoregressive process is also required. This has the added advantage that it provides a means of tracking each individual, yielding predictions for the next observation. The compartment model curve being fitted may also be distorted in other ways. A widely held assumption is that most, if not all, pharmacokinetic concentration data follow a log-normal distribution. By examples, we show that this is not generally true, with the gamma distribution often being more suitable. When extreme individuals are present, a heavy-tailed distribution, such as the log Cauchy, can often provide more robust results. Finally, other assumptions that can distort the results include a direct dependence of the variance, or other dispersion parameter, on the mean and setting non-detectable values to some arbitrarily small value instead of treating them as censored. By pointing out these problems with standard methods of statistical modelling of pharmacokinetic data, we hope that commercial software will soon make more flexible and suitable models available.
    Statistics in Medicine 09/2001; 20(17-18):2775-83. DOI:10.1002/sim.742 · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In clinical phase I trials, pharmacokinetic sampling schedules often have to be modified while the trials proceed. The modifications are based on the observations from a limited number of subjects or only one subject in extreme cases. This paper describes a Kullback-Leibler information approach for modifying pharmacokinetic sampling schedules in clinical phase I trials. The proposed approach presupposes that the pharmacokinetic profile for each subject is specified by an appropriate pharmacokinetic model and the subject-specific parameters. The best modification plan is selected from arbitrarily chosen candidates based on the Kullback-Leibler information. Applications are given to a simulation study and an actual phase I trial of an anti-cancer drug.
    Statistics in Medicine 04/2001; 20(7):1033-49. DOI:10.1002/sim.749 · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Population pharmacokinetic data consists of dose histories, individual covariates and measured drug concentrations with associated sampling times. Population pharmacodynamic data consist of dose histories, covariates and some response measure. Population analyses, whether they be pharmacokinetic or pharmacodynamic attempt to explain the variability observed in the recorded measurements and are increasingly being seen as an important aid in drug development. In this paper a general Bayesian population pharmacokinetic/pharmacodynamic model is described and an analysis of data for the drug recombinant hirudin is presented. The model we use allows for both outliers and censoring in the concentration data and outlying individual pharmacokinetic parameters. We attempt to address directly important questions such as recommended dose size using predictive distributions for response.
    Statistics in Medicine 05/1995; 14(9-10):971-86. DOI:10.1002/sim.4780140917 · 1.83 Impact Factor
Show more